DFgeneric exports lead to superior operating performance

Company
31 May 2024
5 Min read 
  • IPCA Laboratories' operating performance improved in 4QFY24.
  •  Earnings estimates for FY25/FY26 were cut by 12%/14%.
  •  The company is working on scaling up the US generics business.
  •  Sales grew 34.5% YoY in 4QFY24, with strong growth in formulation sales.
  •  The company is expected to deliver a 39% earnings CAGR over FY24-26.
  •  The valuation adequately factors in the upside in earnings.
Login / Open Demat Account to read the report

Never Miss Out on Hot Market Updates

Get exclusive market news delivered to your inbox - on priority